BZ NOTE: Merrimack Pharmaceuticals, As Part Of Its Agreement With Ipsen For The Sale Of Its Oncology Assets Including ONIVYDE, Is Eligible To Receive Additional Payments With The Possibility Of Up To $450M Contingent Upon The Approval Of Potential New Indications For ONIVYDE In The U.S.
Portfolio Pulse from Benzinga Newsdesk
Merrimack Pharmaceuticals may receive up to $450M in additional payments from Ipsen following the sale of its oncology assets, including ONIVYDE, contingent upon the approval of new indications for ONIVYDE in the U.S.
February 13, 2024 | 6:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ipsen's financial commitment to Merrimack Pharmaceuticals for ONIVYDE's new indications in the U.S. could reach up to $450M.
For Ipsen, the commitment to pay up to $450M in additional payments to Merrimack Pharmaceuticals is contingent upon the approval of new indications for ONIVYDE in the U.S. This represents a strategic investment in the drug's potential but also introduces financial risk. The impact on Ipsen's stock price in the short term is likely neutral, as the potential benefits from new approvals are balanced by the significant financial commitment.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Merrimack Pharmaceuticals stands to gain up to $450M in additional payments from Ipsen, conditional on new U.S. approvals for ONIVYDE.
The potential for receiving up to $450M in additional payments is a significant financial incentive for Merrimack Pharmaceuticals. This news could positively impact investor sentiment and the stock price in the short term, as it reflects potential future revenue streams contingent upon the successful approval of new indications for ONIVYDE in the U.S.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90